Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

1 verified discovery matches your filters.

FDA approves talquetamab, a first-in-class bispecific antibody, for heavily pretreated multiple myeloma

Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
Cancer type
Multiple Myeloma
Published
August 13, 2026

In the single-arm, open-label, phase 1/2 MonumenTAL-1 trial, talquetamab produced meaningful, durable responses in patients with heavily pretreated, relapsed or refractory multiple myeloma who had already exhausted the major available…

Primary source cited

Last reviewed